Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$32.54 -2.04%

-$1.24 today

Market cap
$933.51M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.86M

Average 1.00M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$208.51M

FY 2025 · Annual

Investing Cash Flow

-$1.20M

FY 2025 · Annual

Financing Cash Flow

$180.57M

FY 2025 · Annual

+328.7% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Depreciation & Amortization14.15M13.03M7.82M4.39M(4.49M)
Deferred Income Tax8.02M2.71M(140K)00
Stock-Based Compensation94.67M57.32M33.39M21.61M12.65M
Change in Working Capital(23.08M)492K(19.8M)(6.24M)(37.02M)
Accounts Receivables12.4M16.51M4.78M(3.05M)0
Inventory(509K)(3.4M)699K497K0
Accounts Payables(11.69M)3.1M(2.88M)2.67M(625K)
Other Working Capital(23.27M)(15.72M)(22.39M)(6.36M)(36.39M)
Other Non-Cash Items17.41M(9.36M)62.19M(76.51M)(15.58M)
Operating Cash Flow(412.66M)(304.01M)(192.61M)(175.71M)(208.51M)
Capital Expenditures(14.99M)(5.68M)(865K)(1.47M)(171K)
Acquisitions (Net)(217.77M)13.2M065.39M(697K)
Purchases of Investments(960.69M)(467.91M)(511.7M)(261.71M)(285.01M)
Sales of Investments1.18B826.23M650.88M340.36M284.68M
Other Investing Activities217.77M01.25M00
Investing Cash Flow202.78M365.84M139.56M142.57M(1.2M)
Debt Repayment00000
Common Stock Issued33.24M758K30K30.12M180.57M
Common Stock Repurchased000(3M)0
Dividends Paid00000
Other Financing Activities3M750K015M0
Financing Cash Flow36.24M1.51M30K42.12M180.57M
Effect of Forex Changes(92K)(327K)62K(4K)6K
Net Change in Cash(173.74M)63.01M(52.95M)8.98M(29.14M)
Free Cash Flow(427.65M)(309.68M)(193.47M)(177.18M)(208.68M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$164.1M
+ D&A-$4.5M
+ Stock-Based Comp$12.6M
+ Deferred Tax$0
- Working Capital-$37.0M
- Other Non-Cash-$15.6M
= Operating Cash Flow-$208.5M
- Capex-$171.0K
= Free Cash Flow-$208.7M

Analysis

FY2025 free cash flow is -$208.7M. FCF conversion is 127.2% of net income. Operating cash flow was -$208.5M, with capex of -$171.0K. The largest bridge item is Working Capital at -$37.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 13, 2026
8-KCurrent reportNov 13, 2026
8-KCurrent reportNov 12, 2026
SC 13GSC 13G filingNov 10, 2026
S-8S-8 filingOct 20, 2026

Does NKTR generate free cash flow?

Nektar Therapeutics (NKTR) generated -$208.68M of free cash flow in fiscal 2025.

How much operating cash flow does NKTR produce?

Operating cash flow was -$208.51M, before capital expenditures of $171,000.00.